Please ensure Javascript is enabled for purposes of website accessibility
Home / Products / Recombinant Protein / Other Proteins

Recombinant SARS-CoV-2 RBD (Omicron XBB.1.5) Protein, C-His

Catalog #:   EVV00331 Specific References (52) DATASHEET
Applications: ELISA, Immunogen, SDS-PAGE, WB, Bioactivity testing in progress
Expression system: Mammalian Cells
Accession: YP_009724390.1
Protein length: Arg319-Phe541 (G339H, R346T, L368I, S371F, S373P, S375F, T376A, D405N, R408S, K417N, N440K, V445P, G446S, N460K, S477N, T478K, E484A, F486S, F490S, Q498R, N501Y, Y505H)
Overview

Catalog No.

EVV00331

Expression system

Mammalian Cells

Species

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

Protein length

Arg319-Phe541 (G339H, R346T, L368I, S371F, S373P, S375F, T376A, D405N, R408S, K417N, N440K, V445P, G446S, N460K, S477N, T478K, E484A, F486S, F490S, Q498R, N501Y, Y505H)

Predicted molecular weight

27.82 kDa

Nature

Recombinant

Endotoxin level

Please contact with the lab for this information.

Purity

>90% as determined by SDS-PAGE.

Accession

YP_009724390.1

Applications

ELISA, Immunogen, SDS-PAGE, WB, Bioactivity testing in progress

Form

Lyophilized

Storage buffer

Lyophilized from a solution in PBS pH 7.4, 1mM EDTA, 4% Trehalose, 1% Mannitol.

Reconstitution

Reconstitute in sterile water for a stock solution.A copy of datasheet will be provided with the products, please refer to it for details.

Shipping

In general, proteins are provided as lyophilized powder/frozen liquid. They are shipped out with dry ice/blue ice unless customers require otherwise.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.

Alternative Names

Spike glycoprotein, S glycoprotein, E2, Peplomer protein, Spike protein S1, S, Receptor-Binding Domain, RBD, XBB, Omicron XBB, XBB.1.5

Data Image
  • SDS-PAGE
    SDS PAGE for Recombinant SARS-CoV-2 RBD (Omicron XBB) Protein
References

Immunogenicity and Efficacy of Combined mRNA Vaccine Against Influenza and SARS-CoV-2 in Mice Animal Models. [EVV00331]

A combinatorial and computational Tandem approach towards a universal therapeutics against ACE2-mediated coronavirus infections., PMID:40520104

Demonstration and structural basis of a therapeutic DNA aptamer for SARS-CoV-2 spike protein detection., PMID:40516427

Applying Phage Display Technology to Obtain Specific Peptides Blocking Host-Virus Interactions., PMID:40515926

RBD Amplicon Sequencing and Evolutionary Analysis of SARS-CoV-2 Variants from Wastewater Samples., PMID:40515922

Exploring anti-SARS-CoV-2 natural products: dual-viral target inhibition by delphinidin and the anti-coronaviral efficacy of deapio platycodin D., PMID:40512442

Design of SARS-CoV-2 RBD immunogens to focus immune responses toward conserved coronavirus epitopes., PMID:40511920

Conformational Landscaping and Dynamic Mutational Profiling of Binding Interactions and Immune Escape for Broadly Neutralizing Class I Antibodies with SARS-CoV-2 Spike Protein: Distributed Binding Hotspot Networks Underlie Mechanism of Viral Resistance Against Existing Variants., PMID:40510568

Nonstabilized SARS-CoV-2 spike mRNA vaccination induces broadly neutralizing antibodies in nonhuman primates., PMID:40498855

Immune response induced by the recombinant novel coronavirus vaccine (Adenovirus type 5 vector) (Ad5-nCoV) in persons living with HIV (PLWH)., PMID:40498774

Detectable SARS-CoV-2 specific immune responses in recovered unvaccinated individuals 250 days post wild type infection., PMID:40498720

Determination of resilience of a panel of broadly neutralizing mAbs to emerging variants of SARS-CoV-2 generated using reverse genetics., PMID:40496810

Modulation of SARS-CoV-2 spike binding to ACE2 through conformational selection., PMID:40494932

Detecting SARS-CoV-2 cryptic lineages using publicly available whole genome wastewater sequencing data., PMID:40489546

Structural Analysis of the SARS-CoV-2 Spike N-Terminal Domain Across Wild-Type and Recent Variants: A Comparative Study., PMID:40485545

Genetic Variations in TLR2 and TLR4 Genes and Their Association With COVID-19 Severity and Inflammatory Markers in the Moroccan Population., PMID:40483559

Influence of Cholesterol on the Insertion and Interaction of SARS-CoV-2 Proteins with Lipid Membranes., PMID:40474679

GWAS identifies genetic loci for antibody response to SARS-CoV-2 vaccines in patients with systemic autoimmune diseases and healthy individuals., PMID:40463545

Exploring the standardized detection and sampling methods of human nasal SARS-CoV-2 RBD IgA., PMID:40463384

Phylogeny-driven design of broadly protective sarbecovirus receptor-binding domain nanoparticle vaccines., PMID:40463102

Exploring Virus Protein Domains: Detection and Evolutionary Insights., PMID:40455157

Allostery Links hACE2 Binding, Pan-variant Neutralization and Helical Extension in the SARS-CoV-2 Spike Protein., PMID:40447075

Multiplex ACE2-RBD binding inhibition assay: An integrated tool for assessing neutralizing antibodies to SARS-CoV-2 variants and protection against breakthrough infections., PMID:40447072

Development of bivalent RBD adapted COVID-19 vaccines for broad sarbecovirus immunity., PMID:40442110

COVID-19 vaccination and utility of booster dose: A community-based cross-sectional study., PMID:40440923

XBB.1.5 RBD-Based Bivalent Vaccines Induced Antibody Responses Against SARS-CoV-2 Variants in Mice., PMID:40432153

Comparison of Three Commercial ELISA Kits for Detection of Antibodies Against SARS-CoV-2 in Serum Samples from Different Animal Species., PMID:40431727

Individuals Infected with SARS-CoV-2 Prior to COVID-19 Vaccination Maintain Vaccine-Induced RBD-Specific Antibody Levels and Viral Neutralization Activity for One Year., PMID:40431652

Efficient Searches in Protein Sequence Space Through AI-Driven Iterative Learning., PMID:40429882

Rapid and Cost-Effective Diagnostic Blot Assays Based on the Use of Plant-Produced Recombinant Antigens: Lessons Learned from the SARS-CoV-2 RBD Antigen., PMID:40429644

Development of a self-assembling multimeric Bann-RBD fusion protein in Pichia pastoris as a potential COVID-19 vaccine candidate., PMID:40425664

Is SARS-CoV-2 Spike Evolution Being Retargeted at the N-Terminal Domain?, PMID:40415355

Maternal Vaccination and Protective Immunity Against SARS-CoV-2 Infection in Pups., PMID:40411252

Evaluation of broad-spectrum protection by novel mRNA vaccines against SARS-CoV-2 variants (Delta, Omicron-BA.5, XBB-EG.5) in the golden hamster model., PMID:40410742

Comparative study of humoral and cellular immunity against SARS-CoV-2 induced by different COVID-19 vaccine types: Insights into protection against wildtype, Delta and JN.1 omicron strains., PMID:40408899

Passive maternal immunity in children born to women with systemic autoimmune rheumatic disease - A case-control study., PMID:40408885

Food-derived bioactive pigment phycocyanobilin binds to SARS-CoV-2 spike protein both covalently and noncovalently affecting its conformation and functionality., PMID:40404003

Construction of a variable fragment (Fv)-immunoglobulin A (IgA) anti-receptor binding domain (RBD) SARS-CoV-2 library based on IgA from Indonesian COVID-19 survivors., PMID:40403817

Cross-reactive sarbecovirus antibodies induced by mosaic RBD nanoparticles., PMID:40402246

Mass Cytometry Analysis of High-Dimensional Single-Cell Immune Profiles in ZF2001-Vaccinated Patients Infected with SARS-CoV-2., PMID:40384795

Immunogenicity Evaluation of a SARS-CoV-2 BA.2 Subunit Vaccine Formulated with CpG 1826 plus alum Dual Adjuvant., PMID:40383947

An RBD-Fc mucosal vaccine provides variant-proof protection against SARS-CoV-2 in mice and hamsters., PMID:40383816

Analysis of the Total Immunoglobulin G (IgG) and Its Subclasses Over Time in Coronavirus Disease 2019-Recovered Patients and Its Association With Disease Severity: A Single-Center Prospective Cohort Study., PMID:40383689

Nanoparticle-supported, rapid, digital quantification of neutralizing antibodies against SARS-CoV-2 variants., PMID:40383030

Estimating population immunity to SARS-CoV-2 by random sampling from primary and secondary healthcare in Scotland, May 2024., PMID:40381379

Safety and immunogenicity of SARS-CoV-2 protein subunit recombinant vaccine (Indovac®) in healthy populations aged 18 years and above in Indonesia: A phase I, observer-blind, randomized, controlled study., PMID:40381203

A recombinant BCG with surface-displayed antigen induces humoral and cellular immune responses., PMID:40379714

Biophysics of SARS-CoV-2 spike protein's receptor-binding domain interaction with ACE2 and neutralizing antibodies: from computation to functional insights., PMID:40376405

Exploring Diverse Binding Mechanisms of Broadly Neutralizing Antibodies S309, S304, CYFN-1006 and VIR-7229 Targeting SARS-CoV-2 Spike Omicron Variants: Integrative Computational Modeling Reveals Balance of Evolutionary and Dynamic Adaptability in Shaping Molecular Determinants of Immune Escape., PMID:40376091

Electromagnetic waves destabilize the SARS-CoV-2 Spike protein and reduce SARS-CoV-2 Virus-Like particle (SC2-VLP) infectivity., PMID:40374718

Comparative performance of serum and plasma samples in SARS-CoV-2 serology and neutralization assays., PMID:40374015

A multi-antigen vaccinia vaccine broadly protected mice against SARS-CoV-2 and influenza A virus while also targeting SARS-CoV-1 and MERS-CoV. [EVV00331]

Datasheet
$ 480
Product specifications
100 μg 480 1 mg 2880

Contact Information

Order: order@antibodysystem.com

Mail: support@antibodysystem.com

Distributor list

For research use only. Not for human or drug use.

Need help with your order?

Find out more about placing an order here

Recombinant SARS-CoV-2 RBD (Omicron XBB.1.5) Protein, C-His [EVV00331]
Terms of sale Website terms of use Cookie policy Privacy
Copyright © 2025 AntibodySystem SAS. All Rights Reserved.            All Products are for Research Use Only